Current and Emerging Medical Therapies for Primary Hyperhidrosis by Daniel A. Grabell & Adelaide A. Hebert
REVIEW
Current and Emerging Medical Therapies for Primary
Hyperhidrosis
Daniel A. Grabell . Adelaide A. Hebert
Received: August 16, 2016 / Published online: October 27, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Hyperhidrosis is defined as the production of
sweat beyond what is physiologically necessary
to maintain thermal homeostasis. This disease
state may (and typically does) have a significant
impact on the patient’s quality of life.
Medications including antiperspirants,
anticholinergics, and botulinum toxin have
been shown to be effective in the management
of hyperhidrosis. Several medical device
technologies have also proven to be effective.
This review article will explore the current and
emerging pharmacological and medical device
treatments for hyperhidrosis and provide a
framework for treating patients who suffer
with primary forms of hyperhidrosis.
Keywords: Aluminum chloride; Botulinum
toxin; Emerging therapies; Hyperhidrosis;
Iontophoresis
INTRODUCTION
Hyperhidrosis is defined as the production of
sweat beyond what is physiologically necessary
to maintain thermal homeostasis. This
condition can be categorized as primary
(idiopathic) or secondary (related to a known
cause). Several studies have estimated that
1.6–2.9% of the United States population
have been affected by primary hyperhidrosis
[1–7]. One study conducted outside the United
States has reported a prevalence as high as
16.3% of the population [3]. The
pathophysiology of this disorder is poorly
understood but primary hyperhidrosis has
been postulated to have a genetic component.
Studies have shown that 65% of patients with a
diagnosis of primary focal hyperhidrosis
reported a family history of the disease [8]. A
genome-wide linkage analysis showed that
chromosome 14q is possibly associated with
hyperhidrosis [9]. This disease state likely
represents a dysregulation involving both the
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
9AF6F0600CBA195E.
D. A. Grabell  A. A. Hebert (&)
Department of Dermatology, UTHealth McGovern
Medical School, Houston, TX, USA
e-mail: adelaide.a.hebert@uth.tmc.edu
A. A. Hebert
Department of Pediatrics, UTHealth McGovern
Medical School, Houston, TX, USA
Dermatol Ther (Heidelb) (2017) 7:25–36
DOI 10.1007/s13555-016-0148-z
sympathetic and parasympathetic nervous
systems [10, 11].
The diagnosis of primary focal hyperhidrosis
is made via the history and physical
examination with a focus on the consensus
conference diagnostic criteria. The criteria
require at least a 6-month history of focal and
visible sweating without secondary causes [12].
In addition, at least two of the following criteria
must be met: bilateral and symmetric
hyperhidrosis, impairment of activities of daily
living, onset at age less than 25 years old, at
least one episode per week, family history of the
disease, or an absence of symptoms during sleep
[12]. Exclusion of medications that can cause
hyperhidrosis including anticholinesterases,
selective serotonin reuptake inhibitors,
tricyclic antidepressants, glaucoma agents,
bladder stimulants, opioids, and sialagogues
remains essential to ensure proper diagnosis
[13]. The marked impact of primary
hyperhidrosis on a patient’s quality of life has
been measured in clinical trials using the
validated Hyperhidrosis Disease Severity Scale
[14–16]. Treatment of hyperhidrosis has focused
on improving symptoms, reduction of the sweat
and its inherent socially stigmatizing impact,
and subsequently improving the quality of life
of the patients [1]. The objective of this article is
to explore the current and emerging
pharmacological and medical device
treatments for hyperhidrosis and to provide a
framework for treating patients. Surgical
options including curettage, skin excision, and
sympathetic block for hyperhidrosis will be
covered in a separate paper.
METHODS
A search regarding current treatments was
conducted through 5 July 2016 using PubMed,
The Cochrane Library, Google Scholar, Clinical
Key, and Embase. The following keywords were
used to research the literature for references:
‘‘hyperhidrosis’’, ‘‘primary hyperhidrosis’’,
‘‘primary focal hyperhidrosis’’, ‘‘sweating’’,
‘‘excessive sweating’’, ‘‘treatments for
hyperhidrosis’’, and ‘‘treatments for excessive
sweating’’. All relevant English-language
literature was reviewed, and the reference list
of articles of interest were reviewed for further
citations. In addition, clinicaltrials.gov was also
searched using the criteria ‘‘hyperhidrosis’’, and
subsequent literature searches were made on all
new compounds and devices being developed.
This article is a review of existing data from
previously conducted studies that are publically
available and does not involve any new studies




Current therapies for hyperhidrosis are divided
into several categories including topical, oral,
and injectable medications and medical devices.
Topical Therapies
Antiperspirants which usually contain
aluminum salts are the first-line treatment for
hyperhidrosis because of their safety profile,
cost-effectiveness, and efficacy [17–19].
Preparations in the United States can vary in
the amount of metal salts up to 25% depending
on the aluminum compound used [20].
Antiperspirants are believed to work by
obstructing the distal eccrine sweat gland
ducts [19, 21]. Patients with hyperhidrosis who
use these products may develop miliaria due to
the ongoing production of sweat inferior to the
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blocked sweat duct, but long-term blockage
may lead to functional and structural
degeneration of the eccrine acini which does
not cause harm to the patient in the process of
reducing sweat production [21].
A case series published by Scholes et al., in
which 65 patients treated with 20% aluminum
chloride hexahydrate topically nightly for
1 week, then as needed, showed that patients
reported complete control of axillary sweating.
After initial treatment, most patients applied
the substance every 7–21 days which correlated
with epidermal renewal [22, 23]. Aluminum
chloride hexahydrate has been shown to be
effective in palmar hyperhidrosis in a clinical
trial that reported decreased skin water vapor
loss; however, the effect disappeared 48 h after
stopping treatment [19]. Additionally a 6-week
randomized trial of 12 patients showed that
aluminum chloride hexahydrate 12.5% was
equally as effective as 30% for the treatment of
plantar hyperhidrosis [24].
Many patients achieve satisfactory results
with aluminum chloride compounds. In a
study of 691 patients treated with aluminum
chloride solutions, 82% achieved satisfying
results with either complete resolution or a
level of sweating perceived as normal after
initial treatment. In a long-term follow-up
study of these patients, satisfaction levels
increased to 87% with patients using
maintenance therapy [23].
Skin irritation is a common limiting adverse
event with aluminum chloride hexahydrate.
The irritation occurs when the compound is
applied to moist skin allowing the formation of
weak hydrochloric acid [25]. In one study, 36%
of all patients reported moderate irritation and
14% reported severe irritation [23]. Other
adverse effects include itching and stinging on
application which improved with continual
usage [23]. Some studies have shown that
application of a low-potency steroid, such as
topical hydrocortisone, in the morning can
decrease irritation [22, 26]. Applying
aluminum chloride hexahydrate to completely
dry skin greatly reduces the risk of focal skin
irritation [25]. To ensure the skin is dry, some
clinicians have recommended avoiding
washing the axillae prior to the application of
aluminum chloride hexahydrate, drying the
axillae with a blow dryer on a cool setting, or
applying the medication at nighttime and
removing it in the morning [25].
Topical glycopyrrolate 2% is a medication
believed to improve hyperhidrosis through its
anticholinergic properties by competitively
binding the muscarinic acetylcholine receptors
[27]. Several case reports and a few randomized
trials have been conducted to evaluate its efficacy
in facial hyperhidrosis. One study of 25 patients
with facial hyperhidrosis showed that 96% were
partially or fully satisfied with the results of the
medication [28]. Another study of 39 patients
with facial hyperhidrosis showed a reduction of
sweat production on the forehead of 25% 90min
after application with no significant
improvement in the Hyperhidrosis Disease
Severity Scale [29]. However, the results in
axillary hyperhidrosis have been less clinically
meaningful. An uncontrolled study of 35 patients
with axillary hyperhidrosis who had failed
aluminum chloride hexahydrate therapy was
unable to show a consistent and meaningful
benefit from glycopyrrolate compounded in
Cetomacrogol Cream BP [30]. Glycopyrrolate
may be used topically twice daily although some
authors recommend applying it nightly [31].
Patients should be advised to avoid the nose,
mouth, and eyes as the anticholinergic properties
can prevent ocular accommodation [31].
Formaldehyde and glutaraldehyde are not
commonly used in the treatment of primary
focal hyperhidrosis, as these agents can cause
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localized skin irritation, allergic sensitization,
and central nervous system toxicity [25, 32].
Oral Therapies
Oral anticholinergics are a potential treatment
for hyperhidrosis but are occasionally limited by
the side effect profile. A retrospective
chart review of 45 patients with hyperhidrosis
who were prescribed glycopyrrolate showed a
67%response ratewith6patientsnot responding
to treatment and 9 patients discontinuing
therapy secondary to developing adverse events
including dry mouth and gastrointestinal
disturbances [33]. A retrospective chart review
in childrenhas shown improvement in90%of all
patients, with the most common side effects
being dry mouth (26%) and dry eyes (10%) [34].
Oxybutinin, a competitive antagonist at the
postganglionic muscarinic receptors, is another
potential treatment for hyperhidrosis. A
prospective, randomized, placebo-controlled
trial for the initial treatment of hyperhidrosis
showed improvement in greater than 70% of
patients with palmar and axillary hyperhidrosis
and greater than 90% of patients with plantar
hyperhidrosis [35]. A subsequent study showed a
60% improvement in the Hyperhidrosis Disease
Severity Scale and a significant improvement in
the Dermatology Life Quality Index [36]. Dosing
in the literature varies greatly from 2.5 to 5 mg
twice daily with dry mouth being the main
dose-limiting adverse event [35, 37]. Bornaprine
is an oral anticholinergic with limited
commercial availability which has been studied
in hyperhidrosis; however, the central nervous
system adverse events limit the usage of this
medication [38].
Other oralmedicationshave been suggested to
be effective inhyperhidrosis buthave limiteddata
and are of limited value given the availability of
alternative therapies.These includebeta-blockers,
benzodiazepines, methanthelinium bromide,
and clonidine. Beta-blockers, in particular
propranolol, and benzodiazepines, have been
reported to be successful in hyperhidrosis if the
patient is believed to have an anxiety trigger [39].
Oral methanthelinium bromide 50 mg was
compared in a randomized trial which showed a
mean decrease in axillary sweat production of
69 mg in 5 min; however, no significant
difference was seen in palmar sweat production
[40]. Two case reports have shown that clonidine
0.2–0.4 mg is effective in reducing craniofacial
hyperhidrosis [41].
Injectable Therapies
Botulinum toxin is an acetylcholine release
inhibitor and a neuromuscular blocking agent
that is commercially available in the United
States [42, 43]. Each botulinum toxin
(OnabotulinumtoxinA, AbobotulinumtoxinA,
and IncobotulinumtoxinA) has different
characteristics with variable clinical
equipotency ratios that are influenced by the
severity of the underlying disease [44]. A
multicenter, randomized, parallel group,
placebo-controlled trial of 320 patients
evaluated OnabotulinumtoxinA for axillary
hyperhidrosis with a primary endpoint of a
greater than or equal to 50% reduction in
baseline spontaneous axillary sweat
production [45]. At 4 weeks, 94% of patients
on active treatment had met this endpoint,
with 82% maintaining this endpoint at week 16
[45]. Patients who respond to treatment can
have consistent reduction of axillary sweat for
greater than 5 months with repeat dosing
shown to be safe with equal or potentially
increased efficacy [46–48].
Other types of botulinum toxin have limited
data available. Efficacy appears equal between
150 units of AbobotulinumtoxinA and 50 units
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of OnabotulinumtoxinA per axilla; however,
other studies have shown no difference between
100 and 200 units of AbobotulinumtoxinA
[49, 50]. Several other studies have validated a
variety of types of botulinum toxin for palmar
and plantar hyperhidrosis [48, 51–57].
The administration of botulinum toxin
requires multiple injections spaced
approximately 2 cm apart which can pose many
challenges, most notably pain at the injection
site. In order to reduce pain from multiple
injections, several studies have evaluated
different techniques such as using ice, topical
anesthetics, ordiluting thebotulinumtoxinwith
lidocaine. The use of ice packs has been shown to
decrease the discomfort associated with the
multiple needle injections, and this
methodology is cost-effective and
non-threatening to patients [58–60]. Another
cost-effective form of anesthesis is vibration,
which has been shown to reduce patient
discomfort during botulinum injections [61].
Other clinicians have advocated for topical
anesthetics such as tetracaines or lidocaine/
prilocaine cream which have been shown to be
effective but need to be applied 45 min prior to
the procedure [62, 63]. Some studies have even
shown that diluting OnabotulinumtoxinA with
lidocaine instead of normal saline decreases pain
without a loss of efficacy [64, 65]. For patients
with palmar hyperhidrosis who cannot tolerate a
cooling technique, an ulnar, median, and radial
nerve block or a modified Bier Block can be
effective [66–69].
Medical Device Therapies
Iontophoresis, the passing of an ionized
substance through intact skin, is a treatment
method that delivers 15–20 milliamps of current
through tap-water to treat hyperhidrosis [70, 71].
The exact mechanism of action is unclear, but
several hypotheses exist including the inhibition
of sympathetic nerve transmission, ion
deposition obstructing the sweat gland, and
local alterations of pH inhibiting the sweat
gland [72–75]. Initial treatment of 8 sessions in
a 28-day period showed a 81% reduction in sweat
with maintenance therapy required to maintain
the effect [76]. Common adverse events include
discomfort, vesiculation, and erythema [77]. The
impact of iontophoresis can be enhanced if
glycopyrrolate pills are added to the trays before
the iontophoresis is initiated [27, 78–81]. At least
two companies, Hidrex http://www.hidrexusa.
com/ and R.A. Fisher and Co http://www.
rafischer.com/cat_iontophoresis in the United
States, offer iontophoresis units for either sale or
rental.
Microwave thermolysis has also been shown to
be an effective treatment for hyperhidrosis.
Microwaves heat by physical rotations of
molecules with high dipole moment such as the
ionic water in eccrine glands while avoiding low
dipolemomentmolecules such as fat [16]. A study
of a device using this technique in axillary
hyperhidrosis showed a 89% response rate after
treatment with 69% maintaining the effect at
12 months [16]. Adverse events include temporary
tenderness, swelling, and numbness [82].
Adjunctive Therapies
In addition to pharmaceutical and medical
device therapies, several adjunctive therapies
can be helpful to patients. Educating the patient
about the disease state and showing empathy
are critical to increasing compliance with
regimens. The International Hyperhidrosis
Society hosts a website http://www.sweathelp.
org which can serve as a resource for patient
education on the disease state and treatment
options. In addition, several companies with
links on the website offer specialized shirts,
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socks and other footwear that can wick mois-
ture away and prevent wet marks and stains. To
help patients sleep better, moisture-wicking bed
sheets are also available.
EMERGING THERAPIES
FOR HYPERHIDROSIS
Despite many approved therapies, there is still
an unmet need for more effective and
convenient methods for managing
hyperhidrosis.
Topical Therapies
Several topical anticholinergic agents are
currently in development for hyperhidrosis.
Oxybutynin, which has been used off-label for
hyperhidrosis inanoral formulation, is frequently
associated with anticholinergic adverse events
including dry mouth [83]. The adverse events are
believed to be caused by an active metabolite
N-desethyloxybutynin [84]. As a result, a
transdermal gel formulation was approved in the
US for overactive bladder. This gel reduces the
anticholinergic adverse events associated with
oral oxybutynin by avoiding gastrointestinal and
hepatic first pass metabolism which reduces the
level of the active metabolite [84–86]. A study is
currently underway to evaluate oxybutynin gel in
patients with axillary hyperhidrosis. Studies are
also being conducted on umeclidinium,
glycopyrrolate tosylate, and sofpironium
bromide, but limited information is currently
available in peer-reviewed journals.
Medical Device Therapies
Several medical device therapies are currently in
development including radiofrequency
thermotherapy, laser therapy, and ultrasound
therapy. Radiofrequency thermotherapy is a
minimally invasive therapy which utilizes a
device to insert microneedles into the skin and
emit bipolar thermal energy [87]. By focusing
the energy with microneedles, the
thermotherapy is directed to the eccrine sweat
glands in the dermis with minimal trauma to
the epidermis [87]. The efficacy of fractional
microneedle radiofrequency thermotherapy has
been shown in small randomized control trials
to significantly improve the Hyperhidrosis
Disease Severity Score as well as decrease sweat
production [87–89]. In addition,
histopathologic findings have shown a
decrease in the number of sweat glands in
tissue [89]. One study that followed patients
for 1 year found that overweight patients may
need additional treatments to maintain the
effect [90].
Several different types of lasers have been
studied to reduce sweat production with limited
and inconsistent results to date. In a prospective
case–control study of the YAG 1064-nm laser, a
modified starch iodine test showed effective
improvement at 9 months; however, no
significant difference in eccrine glands was
seen in pre- and post-treatment biopsies of the
axillary skin [91]. A study of 21 patients with
axillary hyperhidrosis using the 800-nm diode
laser with a half-side control design showed a
decrease in the sweat rate on the laser-treated
sites but not statistically significantly more than
on the untreated site [92]. A randomized
control trial of 100 patients utilizing the 924-
and 975-nm lasers simultaneously showed an
improvement in the Hyperhidrosis Disease
Severity Score and the modified starch iodine
test at 1 and 12 months of follow-up [93].
Studies of the 1210-nm laser and the 1440-nm
laser for hyperhidrosis are currently being
conducted.
Ultrasound technology is another method to
selectively target the glandular tissue for the
30 Dermatol Ther (Heidelb) (2017) 7:25–36
treatment of hyperhidrosis. In a randomized
double-blind, sham-controlled study of 12
patients with axillary hyperhidrosis utilizing
micro-focused ultrasound with visualization,
83% of all patients experienced a greater than
or equal to 50% reduction in sweat production
as measured using a gravimetric assessment
[94]. In this study, patients followed for
12 months showed long-lasting effects [94].
Another study utilizing the VASER showed
that 11 out of 13 patients had a significant
reduction in sweat production and odor
without recurrence in 6 months [95]. In
addition, ultrasound has been reported to have
been used to induce a therapeutic stellate
ganglion block in a patient with efficacy for at
least a few weeks [96].
DISCUSSION
Hyperhidrosis is a disorder of excess sweat
production which can have a dramatic impact
on a patient’s quality of life. The disease state
appears to have a genetic component, given the
presence of a family history. Hyperhidrosis
likely represents a dysregulation of the
sympathetic and parasympathetic systems.
More research is needed to better understand
the true pathophysiology of the disease process.
A number of topical, oral, and
injectable options are available to treat
hyperhidrosis. Topical antiperspirants are the
first-line agent and are best applied on a dry
surface to prevent irritation of the skin.
Second-line agents and strategies include
oxybutynin, botulinum toxin, and
iontophoresis. Oxybutynin has been shown to
be an effective oral medication which improves
the quality of life in patients with
hyperhidrosis; however, dry mouth is a
common adverse event that may limit the
usage of the medication. Topical formulation
of anticholinergics, including oxybutynin, are
likely to have similar efficacy with less systemic
adverse effects. Injectable botulinum toxin has
also been shown to be effective, but the cost and
pain associated with multiple injections can be
limiting factors. Utilizing cooling agents,
diluting the botulinum toxin in lidocaine, and
performing a nerve block are all effective
methods to reduce the pain.
Many medical device options are currently
used or are in development for hyperhidrosis.
Iontophoresis is a proven method which
works best on palmar and plantar surfaces
and can be enhanced with the addition of
glycopyrrolate. Microwave technology has
been shown to be effective with a
long-lasting effect. Several lasers have been
studied in hyperhidrosis patients; however,
the results to date have been quite mixed and
the role in treating hyperhidrosis remains
unclear. Microneedle radiofrequency and
ultrasound technology are promising new
methods of treatment allowing for a focused
area of thermotherapy targeting the eccrine
sweat glands and potentially developing a
long-term treatment.
CONCLUSION
Clinicians have many effective pharmacological
and medical device options in treating patients
with hyperhidrosis. While no guidelines exist in
the United States, the Canadian Hyperhidrosis
Advisory Committee has developed treatment
algorithms for clinicians to follow [97]. Many
more therapies are currently in development.
Utilizing the best treatment along with
education and empathy will increase a
patient’s compliance and lead to a meaningful
clinical outcome.
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